Flowers Foods fait face à la pression des traitements amaigrissants GLP-1 et d'un sentiment de consommation plus faible.

What happened: Flowers Foods (FLO) faces headwinds from the rising popularity of GLP-1 weight-loss treatments and softer consumer sentiment. A survey found that 6.3% of British households now include a GLP-1 user, nearly tripling in two years, which could reduce demand for baked goods. Meanwhile, FLO's stock has been downgraded by BNP Paribas to $8 from $10, maintaining an 'Underperform' rating.

Market impact: The bakery sector is affected as GLP-1 users save over £400 annually on food, potentially shifting demand away from calorie-dense products like baked goods. Flowers Foods, specifically, is pressured due to its reliance on private label and direct store delivery, which exposes it to changes in consumer behavior. FLO's trailing P/E of 21.30 may also make it less attractive to investors compared to other value stocks.

What to watch next: Investors should monitor FLO's Q1 2023 earnings report (scheduled for May 2, 2023) for insights into how consumer sentiment and GLP-1 treatments are impacting sales. Additionally, keep an eye on regulatory decisions regarding GLP-1 drugs, as changes in accessibility or pricing could further influence demand for weight-loss treatments and, consequently, consumer spending on baked goods.